QATAR BIOBANK RELEASES PILOT PHASE FINDINGS
Two years after it was first announced and after close to 2,000 samples collected voluntarily from citizens and longterm residents, Qatar Biobank has concluded its pilot phase and is ready to ramp up.
The service will create an invaluable resource for personalised medicine and also study the effects of lifestyle, environment and genes on the population, Dr Hanan Al Kuwari, Managing Director of the Hamad Medical Corporation and Chairperson of Qatar Biobank, said at a press conference announcing the findings. It will also help develop treatments and prevent diseases. Obesity, hypertension, diabetes and cardiovascular diseases were found to be prevalent in the sample group, largely stemming from a sedentary lifestyle.
The programme will ramp up in the coming months, going from about 12 participants a day, who come in for the three-hour long procedure that involves interviews and sample collection, to 50 participants a month initially, who will be accommodated in their new, expanded facilities set to be unveiled in the coming months.